Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | EIF4E | P06730 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10109878 | 0.88 | MAPK14 (0.46) | NOTUMPIN1MAPK14 | |
| SCHEMBL419608 | 0.88 | PTGDR2 (0.43) | PTGDR2EIF4ESLC22A12XDHFNTA | |
| SCHEMBL426748 | 0.83 | FNTA (0.47) | PTGDR2FNTAFNTBMAPTTDP1 | |
| SCHEMBL424682 | 0.79 | PTGDR2 (0.38) | PTGDR2SLC22A12TP53MAPTTDP1 | |
| SCHEMBL8236352 | 0.76 | XDH (0.44) | PTGDR2EIF4ESLC22A12XDHFNTA | |
| SCHEMBL8236048 | 0.76 | XDH (0.44) | PTGDR2EIF4ESLC22A12XDHFNTA | |
| SCHEMBL2506409 | 0.75 | PTGDR2 (0.44) | PTGDR2FNTAFNTBMAPTPIN1 | |
| SCHEMBL421510 | 0.74 | MAPK14 (0.45) | EIF4ESLC22A12XDHNOTUMMAPK14 | |
| SCHEMBL14748324 | 0.73 | HPGD (0.52) | MAPTPIN1 | |
| SCHEMBL424378 | 0.73 | RAB9A (0.43) | PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2376482-B1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2376482-B1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2376482-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AiCuris GmbH & Co. KG (DE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010075962-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | TPMT, MAVS, EIF2AK2 | PTGDR2 2860/4885EIF4E 393/4885SLC22A12 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.